IBI 3030
Alternative Names: IBI-3030Latest Information Update: 22 Jan 2026
At a glance
- Originator Innovent Biologics
- Class Antibodies; Antihyperglycaemics; Obesity therapies; Peptide drug conjugates
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Metabolic disorders
Most Recent Events
- 15 Sep 2025 Pharmacodynamics data from the preclinical trials in Metabolic disorders presented at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD-2025)
- 21 Jun 2025 Pharmacodynamics and adverse events data from preclinical trial in Metabolic disorders released by Innovent Biologics
- 20 Jun 2025 Pharmacodynamic data from a preclinical trial in Metabolic disorders presented at 85th Annual Scientific Sessions of the American Diabetes Association (ADA 2025)